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Lysophosphatidic acid (LPA) is a potent bioactive lipid component of oxidized 
low density lipoproteins (oxLDL). High concentrations of LPA have been detected in 
human atherosclerotic plaques. Our data has shown that LPA highly induces smooth 
muscle cell (SMC) migration. Cyr61, a matricellular protein, which also accumulates 
in human atherosclerotic plaques, has been implicated in the injury-induced 
neointimal formation. Smooth muscle cell migration is a key event in the 
development of atherosclerosis, and it contributes to the progressive growth of 
atherosclerotic lesions. Data generated by this study demonstrate that LPA markedly 
induces Cyr61 expression in mouse aortic smooth muscle cells (MASMC). We 
hypothesized that LPA-induced matricellular Cyr61 mediates LPA-induced MASMC 
migration. To date, little is known about the relationship between LPA and Cyr61 in 
smooth muscle cells; the signaling pathway leading to LPA-induced Cyr61 is 
unknown. Furthermore, whether Cyr61 contributes to LPA-induced cell migration is 
unrevealed. Our study demonstrates that LPA, by binding to LPA1 receptor, activates 
the intracellular signaling pathway leading to the activation of PKCwhich in turn 
contributes to the increased expression of Cyr61 in MASMCs. Interestingly, we found 
that after LPA-induced Cyr61 mRNA has been translated into its protein 
intracellularly, the de novo synthesized proteins promptly accumulate in the Golgi 
apparatus and then translocalize to the extracellular matrix. Importantly, our data 
reveal a novel LPA/Cyr61 pathway in controlling MASMC migration. Understanding 
 iv 
the mechanism underlying LPA induction of Cyr61 provides new insight into 
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                      INTRODUCTION 
 
Cardiovascular diseases are the No.1 cause of death in the United States. 
Atherosclerosis is a major component of cardiovascular disease, the primary cause of 
heart disease and stroke. It is the underlying cause of about 50% of all deaths in 
westernized societies. Over the past years, the mechanism of atherosclerosis has been 
more understood. Atherosclerosis is a chronic inflammatory condition, which causes a 
progressive disease characterized by the accumulation of lipids, cells and fibrous 
elements in the large arteries [1].  
 
NORMAL ARTERIES 
The basic components of blood vessels are cells, mostly endothelial cells (ECs) 
and smooth muscle cells (SMCs), and extracellular matrix, which includes collagen, 
elastin and glycosaminoglycans [2]. 
There are three concentric layers (intima, media, and adventitia) in the arterial 
walls. The intima consists of a single layer of ECs with little underlying 
subendothelial connective tissue and is bordered by internal elastic lamina. The 
endothelial cells form a firm barrier between the vessel lumen and the stroma of the 
arterial wall. Research has revealed that endothelial cells regulate a wide set of 
functions in the arterial wall, including vascular tone and structure, and they exhibit 
anticoagulant, antiplatelet, and fibrinolytic properties [3].    
The most prominent constituent of the media layer is smooth muscle cells. These 
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cells are held together by an extracellular matrix which consists mostly of elastic 
fibers and collagen. These cells may also be attached together by junctional 
complexes. The smooth muscle cell is the main contributor to production of the 
extracellular matrix [4]. It is well known that the vascular smooth muscle has the 
function of controlling vascular tone through contraction or relaxation. The vascular 
smooth muscle has also been shown to be involved in the regulation of cell growth, 
death, and migration, as well as matrix modulation and inflammation. These functions 
of vascular smooth muscle play important roles in beneficial physiological vascular 
functions, such as vascular remodeling, and also in pathological disorders, such as 
atherosclerosis, restenosis, transplant vasculopathy, and other vascular diseases [5]. 
The outer limit of the media is defined by the external lamina. The outermost layer 
of the artery is the adventitia, consisting of the connective tissue with nerve fibers and 
the vasa vasorum [6]. The adventitia is thought to be a major source of vasoactive 
factors and a pivotal participant in vascular remodeling. Over the past years the 
researchers noted that the changes occurring in the adventitia may be a signal of 
impending vascular disease, with typical hypercellularity, increased connective tissue 
production, and clear signs of inflammation [7]. 
 
ATHROSCLEROSIS 
Atherosclerosis is a progressive disease caused by the accumulation of lipids and 
fibrous elements in the large arteries. (1) The intimal lesions are called atheromas or 
fibrofatty plaques, which protrude into and obstruct vascular lumina, weaken the 
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underlying media, and finally cause serious complications. Atherosclerosis mostly 
affects elastic arteries and large and medium muscular arteries. As a result, acutely or 
chronically diminished or stopped arterial perfusion leads to lots of severe 
consequences, including mesenteric occlusion, chronic ischemic heart disease, sudden 
cardic death and encephalopathy.  
Due to the overwhelming clinical importance of atherosclerosis, over the past 
decades scientists have put enormous efforts into discovering the mechanism behind 
the diseases. The current concept, called the response to injury hypothesis, considers 
that atherosclerosis is a chronic inflammatory response of the arterial wall initiated by 
injury to the endothelium. Hyperlipidemia, and other risk factors, cause chronic 
endothelia injury, which yields increased permeability, leukocyte adhesion and 
thrombotic potential. As a result, lipoproteins, mostly Low-density Lipoprotein (LDL), 
accumulate in the subendothlial matrix. Meanwhile, blood monocytes adhere to the 
endothelium and migrate into the intima and then are transformed into macrophages. 
 Under the induction of free redicals generated by macrophages or EC, 
accumulated LDL is modified through oxidation, proteolysis, lipolysis and 
aggregation [2][8]. Distinct from native LDL, oxidized LDL can be ingested by 
macrophages through the scavenger receptor, leading to the formation of the foam 
cells. It can also stimulate the overlying ECs to produce a number of proinflammatory 
molecules, including adhesion molecules and growth factors. In the lumen, platelets 
adhere to the endothelial cells and become activated. After being activated, platelets 
release numerous imflammatory factors, and they, together with other factors released 
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by other cells cause the smooth muscle cells to migrate from the media into the intima 
Finally, SMC proliferation and the extracellular matrix that SMCs deposit in the 
intima convert a fatty steak into a mature firbrofatty atheroma, leading to the 
progressive growth of atherosclerosis lesions [2]. Most importantly, in the 
development of atherosclerosis SMC migration and proliferation are key events .   
 
RISK FACTORS: 
Over the past years, epidemiological studies have revealed numerous risk factors 
for atherosclerosis. The well-established familial predisposition to causes of 
atherosclerosis is polygenic. Age, along with other factors, including hyperlipidemia, 
smoking, diabetes mellitus, homocystinemia, contribute to the development of the 
atherosclerosis [2]. Among the risk factors, low density lipoprotein is one of the most 
important risk factors. And the most pathogenic form of LDL is the oxidized LDL. 
 
LYSOPHOPHATIDIC ACID (LPA): 
Oxidized low density lipoprotein (LDL) is an important contributor in the 
pathogenesis of atherosclerosis and its thrombotic complications, such as stroke and 
myocardial infarction. It has been found that lysophosphatidic acid (LPA) is formed 
during mild oxidation of LDL and is the active compound in mildly oxidized LDL and 
minimally modified LDL. LPA also initiates platelet activation and stimulates 
endothelial cell stress-fiber and gap formation. Furthermore, LPA is the primary 
platelet-activating lipid of atherosclerotic plaques, and the amount of LPA within the 
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human carotid atherosclerotic lesion is highest in the lipid-rich core, which is the 
region most thrombogenic and most prone to rupture [9].  
LPA, a potent bioactive lipid, elicits a variety of cellular responses in various cell 
types including proliferation, migration, prevention of apoptosis, cytokine and 
chemokine secretion, platelet aggregation, smooth muscle contraction, and neurite 
retraction. LPA has multiple effects on vessel wall cells and blood platelets. Our group 
has reported that LPA induces the expression of transcription factor, Early Response 
Gene-1 (EGR-1) and coagulation initiator, tissue factor (TF) in aortic smooth muscle 
cells, and promotes interleukin 6 secretion from aortic smooth muscle cells. These 
results imply that LPA might play a role in vascular inflammation and thrombosis 
[10][11][44]. Our recent data and previous studies demonstrate that LPA induces 
smooth muscle cell migration and proliferation. Given the fact that smooth muscle 
cell migration is an important future of atherogenesis, it is of great clinic importance 




LPA is an extracellular ligand for a family of G protein-coupled receptors. 
Through binding to the LPA receptors, LPA activates intracellular signaling pathways, 
which have been shown to be involved in many essential cellular processes [12]. At 
least 5 LPA receptors have been identified. They are LPA1–5, which are widely 
expressed in various cells and mammalian organ systems, such as cardiovascular, 
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nervous and reproductive systems [13]. 
LPA1, also called EDG2, was the first identified LPA receptor [14]. It is highly 
expressed in many organ tissues including brain, heart, lung, thymus, testis, stomach, 
small intestine, spleen, and skeletal muscle in adult mice [15] and has also been 
detected in numerous human tissues such as brain, heart, placenta, spleen, kidney, 
colon, small intestine, prostate, testis, ovary, pancreas, thymus, and skeletal muscle 
[16]. It is reported that LPA1 is involved in cell proliferation, serum-response element 
(SRE) activation, MAPK activation, PLC/PKC activation, Akt activation, and Rho 
activation through three types of G proteins: Gi/o, Gq, and G12/13 [17] [18]. 
LPA2, also called EDG4, was the second LPA receptor identified by sequence 
homology searches using LPA1 [16] [19]. It shows gene express in embryonic brain, 
testis, kidney, lung, thymus, spleen, and stomach in mice [15]. LPA2 has also been 
detected in human tissues including testis, pancreas, prostate, thymus, spleen, and 
peripheral blood leukocytes [16]. Like LPA1, LPA2 signaling is also via three G 
proteins: Gi/o, Gq, and G12/13 [19] [20]. Within MEFs, LPA2 has been shown to have 
redundant functions in mediating PLC activation, proliferation, JNK activation, Akt 
activation, and stress fiber formation [21].  
LPA3, also called EDG7, was identified by degenerate polymerase chain reaction 
(PCR)-based cloning and homology searches [22][23]. LPA3 is found in kidney, lung, 
testis, small intestine, heart, thymus, brain, oviduct, placenta, and uterus in adult mice 
[15]. It is also detected in heart, pancreas, prostate, testis, lung, ovary, and brain in 
humans [22][23]. LPA3 couples to Gi/o and Aug protein, but unlike LPA1 and LPA2, it 
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does not couple to G12/13 [18]. LPA3 signaling induces PLC activation, 
Ca2+mobilization, AC inhibition/activation, and MAPK activation [18][22][23]. 
LPA4, also called p2y9/GPR23, was identified during a “de-orphaning” project of 
G protein-coupled receptors. It is found in human ovary, kidney, skeletal muscle [24] 
and has also been detected in brain, heart, lung, thymus, kidney, skeletal muscle, 
ovary, uterus, and placenta in adult mice. LPA4 signaling couples with Gq/11 and Gs 
proteins [25]. 
LPA5 also called GPR92 was a GPCR closely related to LPA4 [26], sharing at 
most 35% sequence identity with LPA4 and lower identities compared with LPA1–3. It 
is highly expressed in small intestine, and is also detected in spleen and stomach of 
adult mice. It has been demonstrated that LPA5-mediated signaling is relevant to 
normal function, most likely in concert with previously identified receptors [27]. 
 
CYSTEINE-RICH PROTEIN 61: 
Although the extracellular matrix was considered a benign scaffold for arranging 
cells within connective tissues for many years, it is now being redefined as a dynamic, 
mobile, and flexible regulator of cellular behaviour [28]. The ECM can regulate the 
bioavailability and activity of growth factors, chemokines, cytokines and extracellular 
enzymes. Moreover, ECM proteins can also directly interact with cell surface 
receptors, triggering the activation of signal transduction cascades, and regulating 
diverse cellular functions [29].   
The CCN proteins are an important family of matricellular regulatory factors 
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involved in internal and external cell signaling, in angiogenesis, chondro-genesis, and 
osteogenesis, and they probably participate in the control of cell proliferation and 
differentiation [30].  
Cysteine-rich 61 (Cyr61, CCN1) is a Error! Reference source not found. that is 
encoded by the Cyr61 gene [31]. As a member of the CCN protein family, 
CCN1/Cyr61 plays important roles in cell proliferation, adhesion, differentiation, 
angiogenesis and extracellular matrix production. Moreover, CCN1/Cyr61 also has 
many potential functions in tumorigenesis, development, embryo implantation, as 
well as formation of endometriotic lesions. Various agents, including cytokines, 
growth factors, steroid hormones, and some drugs, regulate expression of 
CCN1/Cyr61 through several signaling transduction pathways. As a result, 
CCN1/Cyr61 is not only able to regulate the growth of epithelial cells and fibroblasts, 
but also to induce or suppress apoptosis in a specific cell type [32].   
Cyr61 regulates SMC proliferation, adhesion, migration, differentiation, 
apoptosis, extracellular matrix production, which are important steps in the initiation 
and progression of atherosclerosis, therefore Cyr61 could be one important regulator 
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MATERIAL AND METHODS 
 
MATERIALS: 
LPA (1-Acyl-2-hydroxy-sn-glycerol-3-phosphate) in this study was purchased 
from Avanti Polar Lipids, Inc; transient chambers (6.5 mm diameter, with 8.0 μm pore 
size polycarbonate membranes) were from Corning Costar Corp; and phosphate buffer, 
Harris hematoxylin solution, and eosin Y solution were from Sigma; PD98059 (PD), 
SB203580 (SB), U0126 (U0), GF109203X (GF), GO6976, GO6983, SP600125 (SP), 
Wortmannin, LY294002 (LY) and Rottlerin were from Enzo Life Science. Resveratrol 
was from EMD. Antibody against actin was from Sigma; Antibodies against Mouse 
Cyr61 was from R&D System; Antibodies against adaptin was from BD Transduction 
Laboratories; Antibodies against Egr-1, p-JNK, p-AKT, p-ERK, p-PKD, p-PKC, 
p-PKC, p-P38, p-PKC, p-PKC p-PKC, PKD1, PKD2, and MEK were from Cell 
signaling; Rhodamine Red-X-conjugated AffiniPure goat anti-mouse IgG was from 
Jackson ImmunoResearch Laboratories. Goat anti-sheep IgG Alexa Fluor 488 was 
from Invitrogen; SelectFX Nuclear Labeling Kit and SlowFade Gold antifade reagent 
were from Invitrogen; mouse PKC siRNA, mouse PKC siRNA, mouse PKD1 
siRNA and mouse PKD2 siRNA were from Qiagen; VECTASTAIN ABC kit and 
peroxidase substrate kit DAB were from Vector Laboratories, INC. Hybond-N 
membranes were from GE Healthecare. Trizol reagent was from Invitrogen. GoTaq 
Flexl DNA Polymerase and Reverse Transcription system were from Promega. 
RNeasy Mini Kit was from Qiagen. Recombinant Cyr61 protein was from Abcam. 
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Fast Optical 96-Well Reaction Plaste with Barcode, Taqman Gene Expression Master 




Mouse aorta smooth muscle cells (MASMCs) were prepared from explants of 
excised aortas of mice and rats as described previously [33]. Cells between 10 and 20 
were used in these studies. Cells were cultured in Dulbecco's modified Eagle's 
medium containing 10% fetal bovine serum and 1% glutamine. For Western blot 
assays, cells were starved for 48 hours prior to addition of LPA or other reagents. For 
cell migration assay, prior to the cell migration assay, cells were starved for 24 hours.  
 
SMOOTH MUSCLE CELLS WESTERN BLOT ANALYSIS 
Mouse aortic SMCs (MASMCs) were rinsed with cold PBS and then lysed in cell 
lysis buffer (50 mM Tris–HCl, pH 6.8, 8 M urea, 5%-mercaptoethanol, 2% SDS, and 
protease inhibitors) with sonication for 30 s on ice. After addition of 4X SDS sample 
buffer and incubation at 65 °C for 20 minutes, samples were subjected to 10% SDS 
polyacrylamide gel electrophoresis and were transferred to a polyvinylidene fluoride 
membrane (Immobilon-P, Millipore). The membranes were then probed with the 
specific first antibodies, after being washed in TBST 4 times (5 minutes for each), the 
membranes were incubated in specific second antibodies, which depended on the 
source of the first antibody used, and finally the bands were visualized by ECL Plus 
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(GE Healthcare) as described previously [11]. 
 
CELL MIGRATION ASSAY 
Cell migration was performed using transwell migration plates purchased from 
Corning. Mouse smooth muscle cells were trypsinized and plated onto transwell 
plates for migration assays. A volume of 200 μl media containing 2×10
5
 cells was 
added to the upper chamber. Cells were allowed to migrate through filters (8 μm pore 
size), which had been precoated on both sides with gelatin, in the presence of either 
medium (600 μl) alone or medium with LPA at designated concentrations in the lower 
chamber. Cell migration was carried out at 37 °C in 5% CO2 for 6 h. Cells remaining 
on the upper surface of the filter were carefully removed by mechanical scraping. The 
upper chambers were rinsed with PBS, and the cells were fixed with methanol and 
then stained with Harris hematoxylin and eosinY. The number of cells that had 
migrated to the lower surface of the filter was counted in 4 random objective fields 
(200×magnification) using a Nikon Eclipse E600 microscope. 
 
IMMUNOFLUORESCENCE 
MASMCs grown in 6-well chamber coverglass slides were fixed in 4% ice cold 
paraformaldehyde solution for 30 minutes, permeablized with or without 0.3% triton 
X-100 in PBS for 5 minutes at room temperature, blocked with 5% goat serum 
(Sigma) plus 0.1% Tween-20 in PBS for 1 hour, and then incubated with Cyr61 
antibody and adaptin in 1/100 dilution overnight at 4 °C. After being washed with 
 - 12 - 
mild shaking with PBS 3 times (5 minutes for each), the cells were incubated with the 
secondary antibody, goat anti-sheep IgG Alexa Fluor 488 or Rhodamine 
Red-X-conjugated AffiniPure goat anti-mouse IgG for 2 hours at room temperature. 
Then the cells were washed with PBS 4 times (5 minutes for each) at room 
temperature, and then incubated with DAPI for 2 minutes and washed with PBS 3 
times (5 minutes for each) at room temperature. Subsequently, the coverslips were 
mounted on slides with permanent aqueous mounting medium (Biogenex), and the 




After being stimulated with 5 M LPA for 3, 5, 12, or 24 hours, MASMCs were 
harvested and conditioned media was collected. Secreted Cyr61 was 
immunoprecipitated from conditioned media using the sheep anti-mouse Cyr61 
antibody from R&D System. To detect intracellular Cyr61 protein with the 
immunoprecipitation, cells were homogenized with buffer A (20 mM HEPES, PH7.4, 
50 mM KCl, 2 mM EDTA, protease inhibitor cocktail from ROCHE) by passing 
through 20-gauge needles for 15 times after freezing and thawing 5 times in liquid 
nitrogen and at 37 °C water bath. The homogenized samples were then centrifuged at 
800 x g for 10 minutes to separate the post nuclear supernatant (PNS) from the 
unbroken cells and nuclei. PNS was further subjected to centrifugation at 20,000 x g 
for 1 hour and the pellet was solubilized in buffer B (50 mM PIPES, pH7.0, 150 mM 
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KCl, 5 mM MgCl2,  5 mM CaCl2, and protease inhibitor cocktail with 1% CHAPSO) 
for 1 hour at 4 °C, and then centrifuged again at 20,000 x g for 30 minutes. After the 
supernatant was incubated with the Cyr61 antibody and protease inhibitor cocktail for 
3 hours with rotation at 4 °C, Protein A sepharose beads were added and incubated 
overnight with rotation. The immunocomplex was washed with Buffer B four times 
and then lysed with PARP buffer, the samples were subjected to 10% SDS-PAGE gel. 
 
ADENOVIRAL INFECTION OF MASMCs 
Adenoviruses encoding mouse PKC subtype was constructed as previously 
described [34]. MASMCs were infected for 24 h with either wild type or dominant 
negative PKC adenovirus, then starved for 48 hours followed by treatment either 
with or without LPA. 
 
SMALL INTERFERING RNA (siRNA) TRANSFECTION: 
MASMCs were cultured in RPMI 1640 medium with 10% fetal bovine serum. 
Signal Silence Control siRNA (non-silencing siRNA, 40 nM), Mouse PKC siRNA 
(40 nM), Mouse PKC siRNA (40 nM), Mouse PKD1 siRNA (40 nM), mouse PKD2 
siRNA (40 nM) were transfected according to the manufacturer's instructions (Cell 
Signaling Technology). The Signal Silence Control siRNA was used as a negative 
control. Forty-eight hours after transfection, the cells were trypsinized and transfected 
with siRNA again. After forty-eight hours the cells were starved for 48 h followed by 
treatment either with or without LPA. 
 - 14 - 
 
PREPARATION OF CELL LYSATES AND ECM 
MASMCs were grown in 60 mm dishes and treated as described before. After 
removal of the culture medium and rinsed with PBS, cells were detached from the 
dish by incubation with 1 mM EDTA. The dishes were then rinsed twice with EDTA 
to remove remaining cells. Cellular fractions were lysed with PARP buffer, sonicated 
on ice, added with 4x loading buffer, and incubated in 65 °C for 15 min prior to 
analysis. Extracellular material remaining on the dishes after removal of the cellular 
components was extracted by scraping at 90°C in 1 x Laemmli sample buffer (I x = 60 
mM Tris -HCI, pH 6.8, 2% SDS, 5 % fl-mercaptoethanol, 5% glycerol) . These 
fractions were designated ECM.  
 
NORTHERN BLOTTING ANALYSIS FOR DETECTION OF 
MASMCS CYR61 mRNA: 
Total cellular mRNA was isolated according to the manufacturer’s instruction. 
Total RNA (6-8 g) was subjected to denaturing electrophoresis
 
in 
formaldehyde/agarose gels and was blotted onto Hybond-N membranes. 




cDNA probes. A 0.7 kb 
fragment of mouse Cyr61 cDNA was used to detect Cyr61 mRNA. 18S and 28S 
ribosomal RNA was used as an internal control. 
 
RT-PCR ASSAY: 
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Expression of mRNA was evaluated by RT-PCR. Total RNA was isolated from 
MASMCs and mouse tissues using a Trizol Reagent. The first strand of cDNA was 
reverse transcribed using the reverse transcription system. The cDNA products were 
amplified using GoTaq Flexl DNA Polymerase. The amplification conditions were as 
follows: 5min at 95 °C; 27 to 33 cycles of 30 s at 95 °C, 30 s at 55 °C, and 1 min at 
72 °C; this was followed by a final extension for 10 min at 72 °C. The primers were 
used as follows: LPA1, 5′-AGC TGC CTC TAC TTC CAG C-3′(forward) and 5′-TTG 
CTG TGA ACT CCA GCC AG-3′ (reverse); LPA2, 5′-ATG GGC CAG TGC TAC 
TAC AAC G-3′ (forward) and 5′ AGG GTG GAG TCC ATC AGT G-3′ (reverse); 
LPA3, 5′-GAC AAG CGC ATG GAC TTT-3′ (forward); 5′-CAT GTC CTC GTC CTT 
GTA CG-3′ (reverse)); LPA4, 5′-GTT GTA TTC ATC CTG GGT CT-3′ (forward); 
5′-AGC GAC TCC ATC CTT ATA TG-3′ (reverse); LPA4, 5′-TGC TCT GAC CTT 
GTT GTT CC-3′ (forward); 5′-AGC AAC CCA TAT ACA GCC AGC G-3′ (reverse)). 
The PCR products were analyzed by electrophoresis on a 1.0% agarose gel. 
 
STATISTICS: 
Results are means ± SE. Comparisons between multiple groups were performed 
using one-way ANOVA with post-hoc t-tests. Single comparisons were made using 
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RESULTS 
 
1. Cyr61 is markedly induced by LPA in MASMCs. 
 
1.1 LPA markedly induces Cyr61 protein expression: 
When MASMCs were stimulated with various concentrations of LPA after the 
cells were starved for 48 hours, Cyr61 protein expression increased in response to 
LPA stimulation in a concentration dependent manner with the maximal induction in 
25-200 M (Figure 1). We also observed that LPA induction of Cyr61 protein was 
transient, it increased from 30 minutes and peaked at 3 hours, then declined 
dramatically after 3 to 6 hours (Figure 2). Our data reveal for the first time that LPA 
induces Cyr61 expression in SMCs.  
 
1.2 Induction of Cyr61 mRNA expression by LPA: 
To determine whether LPA induction of Cyr61 protein expression is due to the 
accumulation of Cyr61 mRNA, we examined the effect of LPA on Cyr61 mRNA 
levels. We observed that LPA significantly increased Cyr61 mRNA accumulation in 
quiescent MASMCs. The induction is also transient. The induction peak time is at 
around 1 hour, and declined rapidly after 3 hours (Figure 3).  
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Figure 1. Induction of Cyr61 protein in response to LPA in MASMC. LPA was added to 
quiescent MASMCs at the concentrations indicated above each lane for 3 hours. Cyr61 protein 






Figure 2. Time course of LPA induction of Cyr61 protein in MASMCs. 5 M LPA was added 
to quiescent MASMCs for various times indicated. Cyr61 protein level was determined by western 
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Figure 3. Time course of LPA induction of Cyr61 mRNA in MASMCs. 5 M LPA was added 
to quiescent MASMCs for various times indicated. Total mRNA was isolated, and Cyr61 mRNA 
levels were determined by Northern blot analysis. A mouse Cyr61 cDNA fragment was used as a 
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1.3 LPA receptor expression in MASMCs, mouse aorta and carotid 
arteries. 
To determine the expression levels of LPA1-5 receptors in MASMCs, mouse aorta 
and carotid arteries, total mRNA was extracted and RT-PCR was performed. We 
observed that the expression levels of each type of LPA receptors in these cells and 
tissues were similar, mainly because the major component of mouse aorta and carotid 
arteries is the smooth muscle cells. As shown in figure 4, receptors LPA1, LPA2 and 
LPA4 were highly expressed, LPA3 was expressed at a very low level and there is no 
LPA5 receptor expressed in these cells and tissues. 
 








  The above data showed LPA receptor expression in WT MASMCs, but it is 
still unclear whether up-regulation or down-regulation of the other LPA receptor 
genes occurred when certain LPA receptors were knockout. We have received LPA1 
+/- mice from Dr. Jerold Chun, The Scripps Research Institute and successfully 
established LPA1-/- and LPA2-/- mice and isolated smooth muscles cells from these 
knockout mice. It was reported that LPA3 receptor was dramatically upregulated in 
LPA1 knockout (KO) MASMCs [35], however, it was also reported that in LPA1
-/- 
adult brain, the change in transcript levels of LPA2 and LPA3 gene can not be 





 MASMCs, we extracted total mRNA from each cell type and performed real 
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time PCR. As shown in figure 5, there was no significant difference in the expression 
levels of LPA3 in the LPA1 or LPA2 knockout cells compared to wild type, indicating 
that there is no compensation of LPA3 in LPA1 or LPA2 knockout cells. Our Northern 
blot data and Western blot data confirm this conclusion, as shown in figure 6, there is 
no obvious changes in expression levels of LPA3 in LPA1-2 knockout MASMCs. We 
next determined whether LPA stimulates LPA3 gene expression in WT and LPA1
-/- 
MASMCs. As shown in figure 7, the expression of LPA3 was not changed after LPA 
stimulation, all of the above data strongly supported that LPA3 was not upregulated in 
LPA1-/-, LPA2-/- MASMCs, and LPA stimulation has no effect on LPA3 receptor 
expression, either. 
We also examined whether expression levels of LPA1.2.4.5 receptors were 
upregulated in LPA1-/-, LPA2-/-, LPA3-/- MASMCs. As shown in Figure 5, 6, 8 and 9, 
there was no compensation phenomenon was observed in any of the LPA receptors in 
LPA receptor knockout SMCs. 
 
1.5 LPA receptor LPA1, but not PPAR, mediates LPA-induced Cyr61 
protein expression. 
  To explore the intracellular pathways through which LPA exerts its functions, we 
first evaluated the involvement of LPA receptors. Since LPA1, LPA2 and LPA4 are 
predominantly expressed in MASMCs, we examined which LPA receptor mediated 
LPA-induced Cyr61 protein expression. We stimulated quiescent wild-type LPA1-/- 
and LPA2-/- MASMCs with LPA for 3 hours, and Cyr61 expression was detected by 
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Western blot analysis. We observed that genetic depletion of LPA1 nearly completely 
shut down LPA-induced Cyr61 protein expression; however, genetic depletion of 
LPA2 has no effect on LPA induction of Cyr61 expression, indicating that LPA1 
mediates Cyr 61 expression (Figure 11). To examine whether genetic depletion of 
LPA receptors affect other stimulus-initiated signaling pathway, we determined the 
influence of LPA1-/- and LPA2-/- on the EGF signaling pathway. Quiescent wild-type, 
LPA1-/- or LPA2-/- MASMCs were stimulated with 100 ng/ml EGF for 5 minutes and 
the phosphorylation of MAPKs was detected by Western blot analysis, the results 
showed genetic depletion of LPA1 and LPA2 receptors had no effect on EGF-induced 
phosphorylation of MAPKs (Figure 12). Besides LPA-specific plasma membrane 
receptors, nuclear receptor PPAR-  has also been reported to work as an intracellular 
receptor and to transmit the LPA signal to downstream molecules [37]. To examine 
whether PPAR-  has a role in LPA-induced Cyr61 protein expression in MASMCs, 
we determined the effect of the PPAR-  antagonist GW-9662 on LPA-induced Cyr61 
protein expression. We observed that pretreatment of MASMCs with various 
concentrations of GW-9662 (0.1–10 µM) for 45 min had no effect on the expression 
levels of Cyr61 induced by LPA (Figure 10). The range of the concentrations used is 
based on the information reported previously that 1 µM of GW-9662 efficiently 
blocks PPAR-  activation in vascular SMCs [38]. Our results indicate that the 
PPAR-  pathway is not involved in the LPA induction of Cyr61 protein expression. 
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Figure 4. R-T PCR results, LPA1-5 receptor expression in MASMCs, mouse aortas and 
carotid arteries. Total mRNA from MASMC, mouse aorta and carotid arteries was extracted with 

















                                                                      
Figure. 5. Real time PCR data, LPA1-5 receptor expression in MASMCs. Total mRNA from 
MASMCs was extracted with RNeasy mini kit. After reverse transcription, cDNA was used to 

















LPA1  - 0.87 
LPA2 0.89  - 
LPA3  0.73 0.67 
LPA4  0.93 1.10 
LPA5  -  - 
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Figure 6. A. Western blot analysis showing LPA3 receptor expression in WT, LPA1-/-, LPA2-/- 
and LPA3-/- MASMCs. The tissue samples from mouse lung were used as a positive control, Erk 
has been used as a loading control. B. Northern blot analysis showing LPA3 receptor expression in 
WT, LPA1-/-,LPA2-/- and LPA3-/- MASMCs. Tissue samples from mouse lung were used as a 
positive control, 28S and 18S rRNA were visualized by ethidium bromide staining. C. Total 
mRNA of MASMCs, mouse aorta and carotid arteries was extracted with trizol reagent. After 
reverse transcritption, cDNA was used as template DNA, which was amplified 30 cycles with 














Figure 7. Northern blot analysis data: LPA3 expression levels in WT, LPA1
-/-
MASMCs after 
stimulation with LPA. WT and LPA1
-/-
MASMCs were stimulated with LPA for the time periods 
indicated above, the samples from mouse lung has been used as a positive control, 28S and 18S 




Figure 8. Northern blot analysis, the expression of LPA1, LPA2, LPA4 and LPA5 in WT, 
LPA1-/-, LPA2-/- and LPA3-/- MASMCs. The tissue from mouse lung was used as a positive 
control for LPA1.2, 28S and 18S rRNA were visualized by ethidium bromide staining. 
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Figure 10. GW9662 has no effect on LPA-induced Cyr61 protein expression. Quiescent 
MASMCs were pretreated with GW9662 at the concentrations indicated above for 45 minutes, 
then 5 M LPA was added for 3 hours. Cyr61 protein level was determined by Western blotting 





Figure 11. LPA1, but not LPA2 mediates LPA-induced Cyr61 protein expression. 5 M LPA 




 MASMCs for 3 hours, Cyr61 protein level 























Figure 12. LPA receptors do not mediate EGF-induced signaling pathway. 100 ng/ml EGF 




 MASMCs for 5 minutes, p-ERK, p-MEK, 
and p-P38 were determined by Western blotting with 10% SDS-PAGE gel. The expression of ERK, 
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1.4 MAPKs are not involved in LPA-induced Cyr61 expression. 
  Mitogen-activated protein kinases (MAPKS) are serine/threonine-specific protein 
kinases, which respond to extracellular stimuli and regulate numerous cellular 
activities, such as gene expression, cell differentiation and proliferation. MAPKS 
have several subfamilies, such as extracellular signal-regulated kinases (ERKs), p38, 
c-Jun N-terminal kinases (JNKs). Our data showed that LPA significantly induced the 
phosphorylation of ERK, P38 and JNK in a time dependent manner (Figure 13), these 
results prompted us to determine whether LPA-induced MAPKs play roles in LPA 
induced Cyr61 protein production. MASMCs were pretreated with different 
concentration of ERK inhibitors U0126 and PD98059 for 45 minutes, then 5 M LPA 
was applied to every dish and stayed for 3 hours. The cell lysates were analyzed by 
10% Tris/Glycine SDS-PAGE gel followed by Western blotting with anti-mouse 
Cyr61 and p-ERK antibody. As shown in Figures 14 and 15, treatment with these 
inhibitors didn't block LPA-induced Cyr61 protein expression, indicating that ERK is 
not involved in LPA induction of Cyr61 protein. Using the same strategy, we 
examined the effects of SB203580, a specific p38 inhibitor and SP600125, a specific 
JNK inhibitor on LPA induction of Cyr61 protein expression, as shown in figure 16 
and figure 17, none of those inhibitors had any effect on LPA-induced Cyr61 
expression. This result excludes the possibility that p38 or JNKs plays a role in 
LPA-induced Cyr61 expression. 
 
 





















Figure 13. LPA induces the activation of MAPKs, Akt, and PKD in MASMC. 5 M LPA was 
added to quiescent MASMC. At the time points indicated above, cells were lysed. The 
phosphorylation of MAPKs, AKT and PKD was determined by Western blotting with 10% SDS 
PAGE gel. The expression of MEK and actin was used as the loading control. 
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Figure 14. U0126 doesn't block LPA-induced Cyr61 protein expression. Quiescent MASMCs 
were pretreated with U0126 at the concentrations indicated above for 45 minutes, then 5 M LPA 
was added and stayed in the medium for 3 hours. Cyr61 protein level was determined by Western 




Figure 15. PD98059 doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs were pretreated with PD98059 at the concentrations indicated above for 45 minutes, 
then 5M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by 










Figure 16. SB203580 doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs was pretreated with SB203580 at the concentrations indicated above for 45 minutes, 
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by 






Figure 17. SP600125 doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs were pretreated with SP600125 for 45 minutes, then 5 M LPA was added in the 
medium for 3 hours. Cyr61 protein level was determined by Western blotting with 10% 
SDS-PAGE gel.  Actin was detected as the loading control. 
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1.5 PKD is not involved in LPA-induced cyr61 expression. 
  One of the earliest responses of many cell types to extracellular stimuli is an 
increase in the synthesis of DAG, and protein kinase D (PKD) which is a DAG 
regulated protein kinase that plays a role in mediating some of the cellular responses 
initiated by DAG-producing receptors [39]. Our group has reported thrombin rapidly 
induces PKD phosphorylation [40], angiotensin II induces protein kinase D activation 
[41] and PKD2 regulates LPC-induced PC3 cell migration [42]. LPA also induces 
phosphorylation of PKD in MASMCs (Figure 13), therefore, we determined whether 
PKD is involved in LPA-induced Cyr61 expression. MASMCs were pretreated with 
different doses of Resveratrol, a PKD inhibitor, then 5 M LPA was added, as shown 
in the figure 18, Resveratrol doesn't block LPA-induced Cyr61 expression, suggesting 
PKD is not involved in Cyr61 protein accumulation induced by LPA. Furthermore, 
siRNA transfection experiment has been performed to confirm this result. MASMCs 
were tranfected with PKD1 and PKD2 siRNA for 48 hours, the cells were starved for 
48 h followed by LPA treatment. As shown in figure 19, treatment with neither PKD1 
nor PKD2 siRNA blocked the induction of Cyr61 expression by LPA. Taken together, 
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Figure 18. Resveratrol doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs were pretreated with Resveratrol at the concentrations indicated above for 45 minutes, 
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by 
Western blotting with 10% SDS-PAGE gel. Actin level was used as the loading control. 
 
 
Figure 19. Transfection of PKD1 and PKD2 siRNA doesn’t block LPA-induced Cyr61 
protein expression in MASMCs. MASMCs were transfected with PKD1 and PKD2 siRNA for 
48 hours, after being starved for 48 hours, the cells were stimulated with or without LPA, the 
expression levesl of PKD1 & PKD2 were determined with specific antibodies to monitor the 
knockdown level of Cyr61. Cyr61 protein level was determined by western blotting with 10% 
SDS-PAGE gel. 
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1.6 LPA-induced Cyr61 expression is not mediated by PI3Ks. 
  Phosphoinositide 3-kinases (PI 3-kinases or PI3Ks) include a family of enzymes 
involved in cellular functions such as cell growth, differentiation, motility, 
proliferation, survival and intracellular trafficking. The PI3K pathway is implicated in 
human diseases including diabetes and cancer [43] . Our previous results showed LPA 
significantly induced the phosphorylation of Akt (Figure 13), which is downstream of 
PI3Ks. To determine whether PI3Ks pathway is involved LPA induction of Cyr61, we 
pretreated MSMCs with various concentrations of PI3Ks inhibitor LY294002 and 
Wortmanin for 45 minutes, then incubated the cells with 5 M LPA for 3 hours, as 
shown in Figures 20 and 21, Both inhibitors didn't have any effect on LPA-induced 
Cyr61 protein expression, implying that PI3Ks does not play a role in Cyr61 
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Figure 20. LY294002 doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs were pretreated with LY294002 at the concentrations indicated above for 45 minutes, 
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by 






Figure 21. Wortmannin doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs was pretreated with Wortmannin at the concentrations indicated above for 45 minutes, 
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by 
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1.7 LPA-Induced Cyr61 Expression is mediated by PKC 
  We have excluded the possibility that MAPKs, PKD and PI3Ks were involved in 
LPA induction of Cyr61, so next we want to determine which kinase(s) mediates 
LPA-induced Cyr61 expression. Protein kinase C (PKC) is a family of enzymes, 
which play important roles in many signal transduction pathways by mediating the 
functions of many proteins through the phosphorylation of hydroxyl groups of serine 
and threonine amino acid resides. Our group has reported histamine induces Egr-1 
expression in human aortic endothelial cells via the H1 receptor-mediated protein 
kinase Cdelta-dependent ERK activation pathway [44]. To investigate whether PKC 
mediates LPA-induced Cyr61 protein expression, we pretreated MSMCs with 
indicated concentrations of pan PKC inhibitor GF109203X and GO6983 for 45 
minutes, then incubated the cells with 5 M LPA for 3 hours, as shown in Figures 22 
and 23, Both of those inhibitors dose-dependently block LPA-induced Cyr61 protein 
expression, strongly supporting that PKC mediates LPA induced Cyr61 expression. 
The PKC family consists at least ten isozymes [45], and they are divided into three 
subfamilies, conventional, novel, and atypical based on their second messenger 
requirements. It is unknown which PKC subtype is involved in LPA-induced Cyr61 
expression; our result shows LPA highly induces the phosphorylation of 
PKCFigure 24
To examine whether PKCmediates LPA-induced Cyr61 expression, we 
pretreated MSMCs with various concentrations of PKC inhibitor, Rottlerin and 
PKCinhibitor,GO6976 for 45 minutes, then incubated cells were treated with 5 
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M LPA for 3 hours, as shown in figure 25, Rottlerin markedly blocked LPA-induced 
Cyr61 protein expression in a dose-dependent manner. In contrast, 
PKCinhibitor,GO6976 had no effect on LPA-induced Cyr61 protein expression 
Figure 26. These data strongly support a key role of PKC in mediating 
LPA-induced Cyr61 protein expression.  
To further confirm the above results, we performed small siRNA knockdown 
exprements, MASMCs were tranfected with PKC siRNA for 48 hours; then the cells 
were starved for 48 h followed by treatment of LPA. As shown in figure 27, 
PKCsiRNA completely blocks PKC expression and LPA-induced Cyr61 
expression. In addition, we infected MASMCs with PKCdominant-negative 
adenovirus and wildtype adenovirus, we observed that infection of PKCdominant 
negative adenovirus blocked LPA-induced Cyr61 expression in MASMCs. As a 
positive control, LPA highly induces Cyr61 expression after wildtype 
PKCadenovirus infection in MASMCs (Figure 28). All of those data support the 











Figure 22. PKC inhibitor GF109203X blocks LPA-induced Cyr61 protein expression. 
Quiescent MASMCs were pretreated with GF109203X at the concentrations indicated above for 
45 minutes, then 5M LPA was added in the medium for 3 hours. Cyr61 protein level was 







Figure 23. Go6983 blocks LPA-induced Cyr61 protein expression. Quiescent MASMCs was 
pretreated with GO6983 at the concentrations indicated above for 45 minutes, then 5 M LPA was 
added in the medium for 3 hours. Cyr61 protein level was determined by Western blotting with 
10% SDS-PAGE gel. Actin was detected as the loading control. 
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Figure 24. LPA induces phosphorylation of PKCbut not other PKC subtypes in MASMCs. 
5 M LPA was added to quiescent MASMC at the time points indicated above. Phosphorylation of 
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Figure 25. Rottlerin blocks LPA-induced Cyr61 protein expression. Quiescent MASMCs were 
pretreated with Rottlerin at the concentrations indicated above for 45 minutes, then 5 M LPA was 
added in the medium for 3 hours. Cyr61 protein level was determined by Western blotting with 





Figure 26. GO6976 doesn't block LPA-induced Cyr61 protein expression. Quiescent 
MASMCs were pretreated with G06976 at the concentrations indicated above for 45 minutes, then 
5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by Western 
blotting with 10% SDS-PAGE gel. Actin was detected as the loading control. 
 
 




Figure 27. Transfection of PKC siRNA blocks LPA-induced Cyr61 protein expression in 
MASMCs. MASMCs were transfected with PKC siRNA for 48 hours, after being starved for 48 
hours, the cells were stimulated with or without LPA. Cyr61 protein level was determined by 
Western blotting with 10% SDS-PAGE gel. Actin was detected as the loading control, PKCwas 

























Figure 28. Infection of PKC dominant negative adenovirus blocks LPA-induced Cyr61 
protein expression in MASMCs. MASMCs were infected with type and dominant negative 
PKC viruses for 12 hours, after being starved for 48 hours, the cells were stimulated with or 
without LPA. Cyr61 protein level was determined by Western blotting with 10% SDS-PAGE gel. 
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2. The dynamic localization of LPA-induced Cyr61 
protein in MASMCs. 
 
2.1 LPA markedly induced Cyr61 protein intracellularly and the 
induced Cry61 is deposited in the extracellular matrix. 
Cyr61 is an extracellular matrix protein, it exerts its function mostly in the 
extracellular matrix, and the above data showed that LPA markedly induces Cyr61 
protein expression. To investigate the localization of LPA-induced Cyr61 protein, we 
stimulated quiescent MASMCs with 5 M LPA for various time periods, both cell 
lysates and extracellular matrix were collected and detected with a specific Cyr61 
antibody, as shown in figure 29, after 20 min stimulation, LPA rapidly induces Cyr61 
protein expression intracellularly, however, the increased Cyr61 protein level can only 
be detected in the extracellular matrix after LPA stimulation for 1 hour. All of those 
data demonstrate that LPA rapidly induces Cyr61 protein expression intracellularly 
and the induced Cyr61 translocates outside the plasma membrane and is deposited in 
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Figure 29. LPA highly induces Cyr61 protein expression intracellularly and LPA-induced 
Cyr61 protein is deposited in the extracellular matrix. MASMCs were detached from the 
dishes with 1mM EDTA and lysed in the lysis buffer, and ECM remaining on the culture dishes 
was extracted in Laemmli sample buffer. Cyr61 protein level was determined by Western blotting 
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2.2 The dynamic localization of LPA-induced Cyr61 protein in 
MSMCs. 
Although the above data gave us a brief view the localization of LPA-induced 
Cyr61 protein, it is still unclear that through which subcellular compartments, 
LPA-induced Cyr61 protein is translocated to the extracellular matrix. 
Immunofluorescence analysis has been performed to further explore this question. 
Quiescent MASMCs were stimulated with LPA for various time periods as shown in 
figure 30, after paraformaldehyde fixation, the cells were treated with 0.3% triton 
X-100 for permeabilization of the plasma membrane and then the cells were 
immunostained with the specific antibodies against Cyr61, DAPI ( a specific nuclear 
marker ) and Adaptin ( a specific Golgi apparatus marker ). The results showed that 
intracellular Cyr61 protein was highly induced after 1 hour LPA treatment, moreover, 
the image of LPA-induced Cyr61 protein and Golgi apparatus marker adaptin merged 
together perfectly, indicating that after Cyr61 mRNA being translated into Cyr61 
protein, these proteins immediately accumulate in the Golgi apparatus for further 
processing prior to the secretion into the extracellular matrix. We also observed that 
the intracellular Cyr61 protein induced by LPA decreased after 1 hour, whereas the 
extracellular Cyr61 increased, strongly supporting that LPA-induced Cyr61 proteins 
first accumulated in the Golgi apparatus and then were secreted to the extracellular 
matrix. We also used another approach to directly observe the LPA-induced Cyr61 
deposition on the extracellular matrix. We treated the cells without Triton X100 and 
then immunostained the cells with Cyr61 antibody. As shown in figure 31, Cyr61 
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Figure 30. Dynamic localization of Cyr61 protein induced by LPA. MASMCs were cultured 
on microscope cover glasses, after 48 hours starvation, cells were stimulated with LPA for various 
time periods indicated above; then cells were immunostained with the Cyr61 antibody, DAPI 
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Figure 31. Localization of LPA-induced Cyr61 protein in the extracellular matrix. MASMCs 
were cultured on microscope cover glasses, after 48 hours starvation, cells were stimulated with 
LPA for 3 hours, and then fixed with paraformaldehyde solution followed by immunostaining 
with the specific Cyr61 antibody, DAPI (nuclear marker) antibody, Adaptin (Golgi Apparatus 
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3. Cyr61 mediates LPA-induced MASMC migration. 
 
3.1 Cyr61 is involved in LPA-induced MASMC migration. 
As shown above, our data demonstrate that LPA markedly induces Cyr61 
expression and secretion into extracellular matrix. High concentrations of LPA and 
Cyr61 have been found in atherosclerotic lesions [9][46]. We hypothesize that 
LPA-induced Cyr61 mediates LPA signaling leading to cell migration. To date, 
whether Cyr61 contributes to LPA-induced cell migration is unknown.  
To determine whether LPA-induced MASMC migration is mediated by Cyr61, 
we applied an antibody neutralization approach. We pretreated MASMC with the 
specific Cyr61 antibody for 45 minutes and stimulated the cells with LPA, the cells 
were then subjected to the migration assay, and we observed that LPA-induced cell 
migration was reduced about 80% after the Cry61 antibody treatment, suggesting 
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Figure 32. Cyr61 is involved in LPA-induced MASMC migration. MASMCs were pretreated 
with or without Cyr61 antibody for 45 minutes and then subjected to a migration assay in response 
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3.2 LPA1 receptor and PKC mediate LPA-induced MASMC 
migration. 
As demonstrated above, LPA-induced Cyr61 expression was through LPA1 
receptor and mediated by PKC, and Cyr61 was involved in LPA-induced MASMC 
migration. These data implied that LPA1 receptor and PKC may also play roles in the 
MASMC migration. To determine which LPA receptor mediates cell migration, we 





with LPA. We found that genetic deletion of LPA1, but not LPA2 blocked 
LPA-induced cell migration, indicating that LPA1 but not LPA2 mediates LPA-induced 
MASMC migration (Figure.30). We next determined whether PKC mediated 
LPA-induced MASMC migration, quiescent MASMCs were stimulated with 5 M 
LPA after being pretreated with pan-PKC inhibitor GF109203X for 45 minutes, and 
then subjected to the cell migration assay. As shown in figure 31, PKC specific 
inhibitor GF109203X completely blocked LPA-induced MASMC migration, these 
data indicate that LPA1- and PKC-mediated LPA-induced Cyr61 protein expression is 























Figure 33. LPA induces the MASMC migration, and the migration is mediated by LPA1 




 MASMCs were stimulated 
with 5 M LPA, and then subjected to a migration assay. 
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Figure 34. The effect of GF109203X on LPA-induced MASMC migration. MASMCs were 
pretreated either with or without PKC inhibitor GF109203X for 45 minutes and then subjected to 
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DISCUSSION 
 
One of the important risk factors in the pathogenesis of atherosclerosis is 
oxidized low density lipoprotein (LDL). LPA is one of the most bioactive lipid 
components in oxidized LDL. LPA plays a very important role in initiating platelet 
activation and stimulating endothelial cell stress-fiber and gap formation. It has been 
found that LPA is the most important platelet-activating lipid of atherosclerotic 
plaques and also highly accumulated in lipid-rich core in the atherosclerotic lesion. 
Our group has reported that LPA increased TF mRNA, TF protein, and TF pathway 
activity via transcription factor, Egr-1 [35]. In addition, LPA also prominently induces 
the secretion of IL-6 and monocyte chemoattractant protein (MCP)-1 from human 
aortic SMCs (HASMCs) [47]. These data indicated the important roles of LPA in the 
initiation and progression of atherosclerosis.   
Cyr61 has been shown to be highly expressed in human atherosclerotic plaques, 
correlating with the degree of stenosis and plaque histopathology [46]. The 
upregulation of Cyr61 in VSMCs was first identified in the screening for genes that 
are differentially
 
expressed in response to Ang II stimulation in vascular smooth 
muscle cells [48]. Cyr61 is an extracellular matrix-associated angiogenic inducer that 
promotes cell adhesion, migration, and proliferation. Aberrant expression of Cyr61 is 
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associated with wound healing, and vascular diseases such as atherosclerosis [49]. 
Whether Cyr61 plays a role in LPA-induced cell migration is currently unknown. In 
this study, we determined the relationship between LPA and Cyr61 in VSMCs, and 
their roles in vascular function. Our Western blot analysis and Northern blot analysis 
demonstrate that LPA markedly induces Cyr61 protein and mRNA expression. The 
induction is LPA dose- and time-dependent in MASMCs.  
LPA is well known as an important signaling molecule to produce many cellular 
responses. These responses were explained by both non-receptor and 
receptor-mediated mechanisms. LPA is a direct agonist of the nuclear transcription 
factor PPARgamma [50]. Here our results showed PPARgamma was not involved in 
LPA-induced Cyr61 expression. Currently, there are at least 5 LPA receptors that 
couple with several types of G proteins, Gs, Gi/o, Gq, and G12/13. By activation of 
these G proteins, LPA induces cell proliferation, cell migration, MAPK activation, 
PLC activation, PKC activation, Ca2+ mobilization, Akt activation, and Rho 
activation [17][51][52][53]. It was reported that LPA stimulates prostaglandin E2 
production in cultured stromal endometrial cells through LPA1 [54]. In vascular 
systems, our RT-RCR data clearly showed that LPA1, LPA2 and LPA4 receptors were 
highly expressed. Our group has published the data showing that LPA induces IL-6 
secretion from aortic smooth muscle cells via an LPA1-regulated pathway [49], and 
LPA1 receptor also mediates prostate cancer PC3 cell migration [55]. In this study, 
our Western blot analysis demonstrated that LPA-induced Cyr61 expression was 
mediated by LPA1 receptor, but not LPA2 receptor. Up to date, the signaling pathway 
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involved in LPA induced-Cyr61 expression was unknown. LPA was shown to activate 
MAPKs, Akt and PKD, which are frequently involved in LPA-induced G-protein 
coupled signaling pathways. It has been found that LPA stimulates gastric cancer cell 
proliferation via Erk dependent upregulation of sphingosine kinase 1 transcription 
[56]. Chiu, TT et al., reported in 2007 that protein kinase D2 mediates 
lysophosphatidic acid-induced interleukin 8 production in nontransformed human 
colonic epithelial cells through NF-kappaB [57]. Singla, A et al. reported in 2009 that 
LPA-mediated stimulation of Cl(-)/OH(-) exchange activity was depending on 
activation of phosphatidylinositol 3-kinase/Akt signaling pathway. In this study, our 
Western blot analysis data showed that none of those kinases were involved in 
LPA-induced Cyr61 expression, indicating that an unveiled specific signaling 
pathway leads to LPA-induced Cyr61 expression. 
It was reported that LPA-induced NF-kappaB activation and cytokine production 
were mediated by PKCs but not by JNK, p38 or Erk MAP kinase. Our previous data 
also showed that histamine activates the phosphorylation of PKC and that PKC 
mediates histamine-induced Egr-1 expression in RASMCs and human endothelial 
cells [44]. To investigate whether PKC pathway mediated LPA-induced Cyr61 
expression, we used PKC specific inhibitors, the dominant negative virus constructs 
and siRNA to block the functions of PKCand to knockdown of 
PKCexpressionOur Western blotting results clearly demonstrated that 
LPA-induced Cry61 expression was blocked by each of these approaches, strongly 
supporting our conclusion that PKCmediated LPA-induced Cry61 expression. 
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 Another interesting finding in this study is the dynamic localization of LPA 
induced-Cyr61 protein. Cyr61 is a matricellular protein. It is important to know the 
transportation of Cyr61 protein after Cyr61 mRNA is translated. Our Western blotting 
data demonstrated that the intracellular Cyr61 protein was highly induced by LPA 
stimulation within 20 minutes, and then via Golgi, Cyr61 was secreted into 
extracellular matrix. The peak time difference in Cyr61 protein accumulation in 
intracellular compartment and extracellular matrix suggests a dynamic transportation 
of LPA-induced Cry61 protein from the intracellular compartments to the ECM. Our 
immunocytochemistry results confirmed the Western blot results.  
Atherosclerosis is a chronic arterial disease where vascular smooth muscle cells 
(VSMCs), inflammatory cells, lipids, cholesterol and cellular products like cytockines 
work together to produce a fibro-fatty plaque and initiate neointima formation [58]. It 
has been shown that the neointimal SMCs are derived from the media after balloon 
endothelial denudation or cholesterol-induced injury [59]. The importance of smooth 
muscle cell migration in neointima formation of atherosclerosis is well appreciated. 
Studies have been done to support the role of LPA in the smooth muscle cell 
migration (citation). Zhou et al in 2009 reported LPA induced vascular smooth muscle 
migration via p38 mitogen-activated protein kinase pathway activation [60]. Lin BR 
et al. in 2007 reported that Cyr61 enhanced transendothelial cell migration by 
concomitantly up-regulating chemokine receptor 1 and 2 [61]. It was also reported 
that recombinant Cyr61 protein induces SMC migration in a dose-dependent manner 
[62]. But it was unknown whether Cyr61 played a role in LPA induced MASMC 
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migration. In this study, we found that Cyr61 neutralizing antibody significantly 
blocked LPA-induced MASMCs migration, indicating Cyr61 mediates LPA-induced 
MASMC migration. In addition, our cell migration analysis data clearly demonstrated 
that LPA-induced MASMC migration is mediated by LPA1 and PKC kinase. LPA1 
and PKC are responsible for LPA-induced Cyr61 expression.  
Taken together, the above results demonstrate that LPA, via LPA1 receptor, 
activates a specific signaling pathway leading to PKC activation, which in turn, 
mediates LPA-induced Cyr61 protein in MASMCs. LPA-induced Cyr61 proteins first 
accumulated in the Golgi apparatus then were secreted into extracellular matrix. Our 
data further show that LPA-induced Cyr61 is responsible for LPA-induced SMC 
migration, which may contribute to the development of atherosclerosis. The 
identification of the specific LPA receptor and PKCdelta, especially the novel 
LPA/Cyr61 pathway in controlling smooth muscle cell migration, provides new 
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Figure 36. A diagram showing the signaling pathway by which LPA induces Cyr61 and 
MASMC migration.
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